Femoral Nerve Block for Analgesia After Anterior Cruciate Ligament Reconstruction
Information source: Mahidol University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Analgesia After ACL Reconstruction
Intervention: 0.25% Bupivacaine (Drug); 0.5% Bupivacaine (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Mahidol University Official(s) and/or principal investigator(s):
arissara iamaroon, Principal Investigator, Affiliation: Mahidol University
Summary
Femoral nerve block using 0. 25% bupivacaine or 0. 5% bupivacaine provides a longer time for
analgesia after Anterior Cruciate Ligament (ACL) reconstruction.
Clinical Details
Official title: Femoral Nerve Block Using 0.25% Versus 0.5% Bupivacaine for Analgesia After Arthroscopic Anterior Cruciate Ligament Reconstruction
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: time to first analgesic requirement
Secondary outcome: pain score scale
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patients scheduled for ACL reconstruction
- ASA physical status I-II
- Body weight > or = 50 kg.
Exclusion Criteria:
- Patients with redo ACL reconstruction
- Contraindication to neuraxial block
- allergy to local anesthetics, sulfa, NSAIDs, morphine, paracetamol
- Patients with communication problem
Locations and Contacts
Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand
Additional Information
Starting date: April 2011
Last updated: April 8, 2015
|
